Chris Coughlin Elected to Hologic Board of Directors
MARLBOROUGH, Mass., March 2, 2016 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced today that Christopher J. Coughlin has joined the Company's Board of Directors. Mr. Coughlin was elected to the Board at the Company's 2016 Annual Meeting of Stockholders, along with nine existing Directors who were re-elected.
Mr. Coughlin, who in December was named "Director of the Year" by the National Association of Corporate Directors, has extensive senior leadership experience, including as the former Chief Financial Officer of Tyco International. He has held executive operating and financial positions at the Interpublic Group, Pharmacia and Nabisco International. Mr. Coughlin currently serves on the boards of Allergan (formerly Actavis), Alexion Pharmaceuticals and Dun & Bradstreet, where he is Chairman of the Board. He previously served on the boards of Covidien, Dipexium Pharmaceuticals, Forest Laboratories, the Interpublic Group, Monsanto and Perrigo.
"It is a pleasure to welcome Chris to Hologic's Board," said Steve MacMillan, the Company's Chairman, President and Chief Executive Officer. "He is a proven business leader who brings a strong track record of value creation. His depth of experience in executive leadership roles within complex corporate organizations, his financial background, and his experience on public company boards will contribute critical insights in Hologic's efforts to generate sustainable growth and shareholder value."
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products. The Company's core business units focus on diagnostics, breast health, GYN surgical, and skeletal health. With a unified suite of technologies and a robust research and development program, Hologic is dedicated to The Science of Sure. For more information on Hologic, visit www.hologic.com.
This news release contains forward-looking information that involves risks and uncertainties, including statements about the Company's plans, objectives, expectations and intentions, and statements regarding the Company's Board of Directors. These forward-looking statements are based on assumptions made by the Company as of this date and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. These risks include, but are not limited to, the risk that the Company may not be able to attract and retain qualified Board members or executives. These risks are not exhaustive. Other factors that could adversely affect the Company's business and prospects are described in the filings made by the Company with the SEC. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented here to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
Vice President, Investor Relations and Corporate Communications
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/chris-coughlin-elected-to-hologic-board-of-directors-300229079.html
SOURCE Hologic, Inc.